🇺🇸 Bupivacaine-epinephrine in United States

43 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 43

Most-reported reactions

1. Cardiac Arrest — 7 reports (16.28%)
2. Somnolence — 6 reports (13.95%)
3. Accidental Overdose — 5 reports (11.63%)
4. Agonal Rhythm — 4 reports (9.3%)
5. Bradycardia — 4 reports (9.3%)
6. Electrocardiogram Qrs Complex Shortened — 4 reports (9.3%)
7. Facial Bones Fracture — 4 reports (9.3%)
8. Delirium — 3 reports (6.98%)
9. Drug Ineffective — 3 reports (6.98%)
10. Heart Rate Increased — 3 reports (6.98%)

Source database →

Frequently asked questions

Is Bupivacaine-epinephrine approved in United States?

Bupivacaine-epinephrine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Bupivacaine-epinephrine in United States?

Lumbini Medical College is the originator. The local marketing authorisation holder may differ — check the official source linked above.